Related Experiment Videos
An FHIT tumor suppressor gene?
M M Le Beau1, H Drabkin, T W Glover
1Section of Hematology/Oncology, University of Chicago, Illinois 60637, USA. mmlebeau@mcis.bsd.uchicago.edu
Genes, Chromosomes & Cancer
|April 29, 1998
Summary
The FRA3B fragile site and the FHIT gene are located in a large, unstable genomic region. Evidence suggests FHIT
Area of Science:
- Genetics
- Cancer Biology
- Molecular Oncology
Background:
- The FRA3B fragile site at 3p14.2 is a common aphidicolin-inducible fragile site.
- Band 3p14 is implicated in various human tumors due to deletions and rearrangements.
- The FHIT gene, located in 3p14.2, is a candidate tumor suppressor gene.
Purpose of the Study:
- To summarize evidence for and against FHIT's role as a tumor suppressor gene.
- To outline experimental approaches for validating FHIT's tumor suppressor function.
- To discuss the challenges in confirming candidate tumor suppressor genes in unstable genomic regions.
Main Methods:
- Review of existing literature on FRA3B and FHIT.
- Analysis of evidence regarding FHIT transcript aberrations in cancers.
- Discussion of experimental validation strategies for tumor suppressor genes.
Main Results:
- FRA3B is a large (≥500 kb) unstable region lacking typical fragile site repeat motifs.
- Aberrant FHIT transcripts are found in numerous cancer cell lines and tumors.
- Conflicting evidence exists regarding FHIT's classical tumor suppressor role, potentially due to its location.
Conclusions:
- Confirming FHIT as a tumor suppressor gene is challenging due to its location in the unstable FRA3B region.
- The instability of FRA3B may confound the interpretation of FHIT's role in tumorigenesis.
- Further experimental evidence is required to definitively establish FHIT's function as a tumor suppressor in human cancers.